Interstitial lung disease: Current concepts of pathogenesis, staging and therapy

The American Journal of Medicine

Volumn 70, Issue 3, 1981, Pages 542-568

  Crystal, Ronald G ^a   Gadek, James E ^a   Ferrans, Victor J ^a   Fulmer, Jack D ^b   Line, Bruce R ^a   Hunninghake, Gary W ^a  

^a Birmingham Alabama UK ^*

^b Birmingham   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM 67; RADIOISOTOPE;

ETIOLOGY; HISTOLOGY; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG FIBROSIS; PATHOGENESIS; RESPIRATORY SYSTEM; REVIEW; SCINTISCANNING;

ADRENAL CORTEX HORMONES; BIOPSY; CHEMOTACTIC FACTORS; GALLIUM RADIOISOTOPES; HUMANS; IRRIGATION; LUNG; LYMPHOCYTE ACTIVATION; MACROPHAGES; PULMONARY ALVEOLI; PULMONARY FIBROSIS; T-LYMPHOCYTES;

EID: 0019435091     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(81)90577-5     Document Type: Review

References (245)

1. Interstitial lung disease
2. Diffuse pulmonary alveolar fibrosis
3. Interstitial pneumonia
4. Reactions of the interstitial space to injury
5. The biochemical basis of pulmonary function
6. Idiopathic pulmonary fibrosis: clinical, histologic, radiographie, physiologic, scintigraphic, cytologic, and biochemical aspects
7. The connective tissue of lung
8. Cold-insoluble globulin (fibronectin) in connective tissues of adult human lung and in trophoblast basement membrane
9. The fibroblast of the human alveolar structures; a differentiated cell with a major role in lung structure and function. Human tissues and cells in biomedical research
10. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage
11. Respiratory Diseases Task Force: Report on problems, research, approaches, and needs
12. Crackles (rales) in the interstitial pulmonary diseases
13. The pathology of honeycomb lung
14. A new type of hypersensitivity pneumonitis in Japan
15. Interstitial pneumonia from mitomycin
16. Acute hypersensitivity pneumonitis associated with carbamazine therapy
17. Whipple's disease of the lung
18. Pulmonary radiographic findings in a case of febrile, relapsing, nonsuppurative panniculitis (Weber-Christian Disease)
19. Hermansky-Pudlak syndrome. Pulmonary manifestations of a ceroid storage disease
20. Cells, collagen and idiopathic pulmonary fibrosis
21. Interstitial associations of cells lining air spaces in human pulmonary fibrosis
22. Population characteristics of the cells of the normal lung
23. Nongranulomatous interstitial pneumonitis in sarcoidosis: relationship to the development of epithelioid granulomas
24. Immunopathogenesis of hypersensitivity pneumonitis
25. Response of the lung to inhaled antigens
26. Histopathology of sarcoidosis and its immunological basis
27. Morphogenesis and development of sarcoid lesions. Similarities to the group of collagenoses
28. Structure and function in sarcoidosis
29. Farmer's lung: a study of an acute fatal case
30. Immunopathological studies in patients with farmer's lung
31. Diffuse pulmonary fibrosis
32. Experimental interstitial pulmonary fibrosis
33. Experimental fibrosing alveolitis
34. Experimental immune complex disease of the lung The pathogenesis of a laboratory model resembling certain human interstitial lung diseases
35. Acute hypersensitivity pneumonitis. Serial changes in lung lymphocyte subpopulations following exposure to antigen
36. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice
37. Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology
38. Development of experimental radiation pneumonitis
39. Significance of basal lamina for regeneration of injured lung
40. The human alveolar macrophage
41. Quantification, origin, and fate of pulmonary macrophages
42. Direct evidence for a bone marrow origin of the alveolar macrophage in man
43. Proliferative capacity of the human alveolar macrophage
44. Role of monocytes and interstitial cells in the generation of alveolar macrophages
45. Regulation of release of the alveolar macrophage-derived chemotactic factor
46. The in vivo effects of quartz on alveolar macrophage membrane topography and the characteristics of intrapulmonary cell populations
47. The importance of lymphocytes in pulmonary health and disease
48. Immunocompetent cells from the lower respiratory tract of normal human lungs
49. Localization of the immune response in sarcoidosis
50. Immunoglobulin secreting cells in normal human bronchial lavage fluids
51. Lung immunoglobulin production in chronic lung disease
52. Increased bronchoalveolar IgG-secreting cells in interstitial lung diseases
53. IgG on lymphocyte surfaces technical problems and the significance of a third cell population
54. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage
55. Mechanisms by which cigarette smoke attracts polymorphonuclear leukocytes to lung
56. Analysis of bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis
57. Granulomatous inflammations
58. Maintenance of granuloma formation in pulmonary sarcoidosis by T-lymphocytes within the lung
59. Bronchoalveolar lymphocytes in sarcoidosis
60. Immunologic abnormalities in sarcoidosis
61. Comparison of the alveolitis and idiopathic pulmonary fibrosis
62. Local pulmonary immunity in pigeon breeder's disease
63. Peripheral blood lymphocyte subpopulations in sarcoidosis
64. Lymphocyte subpopulations in sarcoidosis: correlation with disease activity and duration
65. Bronchoalveolar lavage in interstitial lung disease
66. Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis
67. Pathogenetic studies in idiopathic pulmonary fibrosis: control of neutrophil migration by immune complexes
68. Circulating immune complexes in the idiopathic interstitial pneumonias
69. Therapeutic decisions in sarcoidosis: prospective evaluation of the effect of corticosteroids on lavage lymphocytes and 67 Gallium scans
70. Mechanisms for the inflammatory response in primate lungs; demonstration and partial characterization of an alveolar macrophage chemotactic factor with preferential activity for polymorphonuclear leukocytes
71. Immunologic reactivity of the lung. VI. The in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages
72. Human alveolar macrophage chemotactic factor for neutrophils: stimuli and partial characterization
73. Alveolar macrophage-derived chemotactic factor Kinetics of in vitro production and partial characterization
74. Release of phagocyte and lymphocyte chemotactic factors by alveolar macrophages
75. Generation of a human polymorphonuclear leukocyte (PMN) chemotactic factor by the lipoxygenase pathway of alveolar macrophage (AM)
76. Alveolar macrophage-neutrophil interaction: a role for inflammatory cell cooperation in the disruption of connective tissue
77. Interaction of the alveolar macrophage (AM) and the circulating neutrophil. AM-induced neutrophil activation
78. Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis
79. Neutrophil-mediated fibroblast destruction in idiopathic pulmonary fibrosis (IPF)
80. Cellular and protein content of bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis and asbestosis
81. Idiopathic pulmonary fibrosis and asbestosis: pathogenetic parallels
82. Inflammation and asbestosis. Characterization and maintenance of alveolitis following acute asbestos exposure
83. Oxygen-dependent microbial killing by phagocytes
84. Oxygen-dependent microbial killing by phagocytes
85. Biosynthesis of serum complement
86. Prostaglandin secretion in rabbit alveolar macrophages and its relationship to phagocytosis
87. Secretion of a specific collagenase by stimulated macrophages
88. Activation of alveolar macrophage collagenase by a neutral protease secreted by the same cell
89. Elastase-like esteroprotease activity in human and rabbit alveolar macrophage granules
90. Secretion of plasminogen activator by stimulated macrophages
91. Changes in cellular enzyme levels and extracellular release of lysosomal acid hydrolases in macrophages exposed to group A streptococcal cell wall substance
92. Activated macrophages induce vascular proliferation
93. Pulmonary macrophages release a factor that stimulates human lung fibroblasts to replicate
94. Macrophage-lymphocyte interaction and lymphocyte recognition
95. Secretory function of mononuclear phagocytes
96. Mechanisms of extracellular killing of nucleated mammalian cells by macrophage
97. Production of colonystimulating factor by human macrophages
98. Chemotaxis of rat lymphocytes
99. Products of activated lymphocytes. Leukocyte inhibitory factor (LIF) distinct from migration inhibitory factory (MIF)
100. Leukocyte chemotactic factors produced by sensitized lymphocytes
101. Physicochemical characterization of chemotactic lymphokines produced by human T and B lymphocytes
102. Interaction of soluble C3 fragments with guinea pig lymphocytes: comparison of effects of C3a, C3b, C3c, and C3d on lymphokine production and lymphocyte proliferation
103. Lymphocyte-macrophage interactions and macrophage activation in the expression of antimicrobial immunity in vivo
104. Conditions determining the generation and expression of T helper cells
105. Superoxide production by phagocytic leukocytes
106. Human granulocyte generation of hydroxyl radical
107. A peroxidase-mediated antimicrobial system in leukocytes
108. Human granulocyte collagenase
109. Granulocyte collagenase selective digestion of type I and type III collagen
110. Extracellular release by human neutrophils (PMNs) of a latent collagenase stored in the specific (secondary) granules
111. Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes
112. Independent effects of IgG and complement upon human polymorphonuclear leukocyte function
113. Functional differentiation of human neutrophil granules: generation of C5a by specific (secondary) and inactivation of C5a by azurophil (primary) granule contents
114. C5 chemotactic factor induces leukocyte production of tissue factor activity. A link between complement and coagulation
115. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes as in vitro model of immune vascular damage
116. Biopsy of diffuse pulmonary lesions
117. Open-lung biopsy in diffuse pulmonary disease
118. The definitive evaluation of sarcoidosis
119. Open lung biopsy. Nineteen-year experience with 416 consecutive operations
120. Transbronchial lung biopsy for the diagnosis of sarcoidosis
121. Transbronchial lung biopsy via the fiberoptic bronchoscope in sarcoidosis
122. The role of transbronchial lung biopsy in diffuse pulmonary disease
123. The role of fiberoptic bronchoscopy in the diagnosis of sarcoidosis
124. Clinical implications of a “nonspecific” transbronchial biopsy
125. Transbronchial lung biopsy for diffuse pulmonary diseases. Results in 939 patients
126. Comparison of transbronchial and open biopsy in chronic diffuse infiltrative lung disease
127. Sensitivity and specificity of the nonspecific transbronchial lung biopsy
128. Pathologic changes in the peripheral airways of young cigarette smokers
129. Relation of smoking and age to findings in lung parenchyma: a microscopic study
130. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis
131. The specificity and nature of serum-angiotensin-converting-enzyme (serum ACE) elevations in sarcoidosis
132. Markedly elevated angiotensin converting enzyme in lymph nodes containing non-necrotizing granulomas in sarcoidosis
133. Elevated serum angiotensin I converting enzyme in sarcoidosis
134. Angiotensin converting enzyme (ACE) and lysozyme (L) levels in serums of patients with sarcoidosis (abstract)
135. Angiotensin-I-converting enzyme and gallium scan in noninvasive evaluation of sarcoidosis
136. Serum angiotensin converting enzyme activity in sarcoidosis as measured by a simple radiochemical assay
137. Usefulness of serum lysozyme measurement in diagnosis and evaluation of sarcoidosis
138. Serum lysozyme in sarcoidosis: evaluation of its usefulness in determination of disease activity
139. Auto-antibody studies in interstitial pulmonary fibrosis
140. Evidence for circulating immune complexes in sarcoidosis
141. Pulmonary and extrapulmonary sarcoidosis in relation to circulating immune complexes
142. Circulating immune complexes in erythema nodosum and early sarcoidosis
143. Lymphocyte subpopulations in sarcoidosis: correlation with disease activity and duration
144. Respiratory disease in coal miners
145. Extrinsic allergic alveolitis
146. Pulmonary histiocytosis X
147. Lymphangioleiomyomatosis physiologic-pathologic radiologic correlations
148. Normal chest roentgenograms in chronic diffuse Infiltrative lung disease
149. Clinical-pathologic approach to diffuse infiltrative lung disease
150. Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs)
151. Types of fibrosis in coal workers' pneumoconiosis
152. The value of radiologic-pathologic correlation in the education of the radiologist
153. UICC/Cincinnati classification of the radiographic appearances of the pneumoconioses
154. The end-stage lung
155. Natural history and treated course of usual and desquamative interstitial pneumonia
156. Pulmonary function in stage I and II pulmonary fibrosis
157. Morphologic-physiologic correlates of the severity of fibrosis in idiopathic pulmonary fibrosis
158. Radiographic pathologic correlations in interstitial pneumonias
159. Correlated studies of interstitial pulmonary disease
160. Gallium-67 citrate scanning in neoplastic and inflammatory lesions
161. 67Ga-scintigraphy in non-malignant lung diseases
162. 67Ga-citrate scanning
163. 67Ga in pneumoconiosis
164. 67Ga accumulation in pulmonary lesions associated with bleomycin toxicity
165. 67Gallium citrate lung scans in interstitial lung disease
166. Gallium-67 citrate scanning in the staging of idiopathic pulmonary fibrosis. Correlation with physiological and morphologic features and bronchoalveolar lavage
167. Serial 67 Gallium lung scanning in pulmonary eosinophilic granuloma
168. 67Ga association with lymphocytes
169. Fluid and cellular melieu of the human respiratory tract
170. Analysis of bronchoalveolar lavage in normal humans and patients with diffuse interstitial lung diseases
171. Characterization of the inflammatory and immune effector cells in lung parenchyma of patients with interstitial lung disease
172. Assessment of bronchoalveolar lavage (BAL) analysis in the diagnosis of patients with interstitial lung diseases
173. Quantitation of inflammatory activity in interstitial pneumonitis by bronchofiberscopic pulmonary lavage
174. Enzymes in bronchoalveolar lavage fluid from patients with asbestos exposure
175. Immunoglobulin content in the bronchial washings of patients with benign and malignant pulmonary disease
176. Sarcoidosis analysis of cells obtained by bronchial lavage
177. Langerhans cells and lung interstitium
178. Cigarette smoking and lung parenchymal injury: mechanisms by which cigarette smoke attracts polymorphonuclear leukocytes to lung
179. Composition of the surface active material
180. Immunoglobulins in the bronchial washings of patients with chronic obstructive pulmonary disease
181. Biochemical analyses of bronchoalveolar lavage fluids of healthy human volunteer smokers and nonsmokers
182. Living histamine containing cells from bronchial lumens of humans. Description and comparison of histamine content with cells of Rhesus monkeys
183. Immunoglobulin A system in the respiratory disease
184. Alpha-1-antitrypsin content in serum, alveolar macrophages, and alveolar lavage fluid of smoking and nonsmoking normal subjects
185. Collagen synthesis and collagenase production by human lung fibroblasts
186. Etude ultrastructurale des liquides de lavage broncho-alveolaire (LBA) chez l'homme
187. Pulmonary sarcoidosis: Pathogenesis and therapy
188. Inflammatory and immune characteristics of idiopathic pulmonary fibrosis
189. Therapy decisions in sarcoidosis. Prospective use of bronchoalveolar lavage and gallium-67 scanning
190. Corticosteroids and lymphoid cells
191. Glucocorticosteroid therapy: mechanisms of action and clinical considerations
192. Glucocorticoid suppression of macrophage migration inhibitory factor
193. Influence of steroid treatment: response in sarcoidosis
194. Suppression of macrophage arming by corticosteroids
195. Suppression of the human autologous mixed lymphocyte reaction by physiologic concentrations of hydrocortisone
196. The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes
197. Glucocortisteroids administered in vivo inhibit human suppressor T-lymphocyte function and diminish B-lymphocyte responsiveness in in vitro immunoglobulin synthesis
198. Mechanisms of corticosteroid action on lymphocyte subpopulations
199. Immunological reactivity of the lung. III. Effects of corticosteroids on alveolar macrophage cytotoxic effector cell function
200. The effect of adrenal glucocorticosteroids upon the cellular composition of inflammatory exudates
201. Biochemical actions of glucocorticoids on macrophages in culture. Specific inhibition of elastase, collagenase and plasminogen activator secretion and effects on other metabolic functions
202. Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprin or D-penicillamine
203. Treatment of the Hammand-Rich syndrome with cortisone
204. The prognosis of cryptogenic fibrosing alveolitis
205. Corticosteroid treatment of diffuse interstitial pulmonary fibrosis
206. Sarcoidosis
207. A 10 year study of corticosteroid treatment of pulmonary sarcoidosis
208. A long-term study of sarcoid and its modification by steroid therapy
209. Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy
210. A controlled trial of prednisone treatment of sarcoidosis
211. The present status of treatment of pulmonary sarcoidosis: a house divided
212. Extended experience in the long-term corticosteroid treatment of pulmonary sarcoidosis
213. The problem of the treatment of sarcoidosis: report of the subcommittee on therapy
214. State of the art-pulmonary disorders associated with the collagen vascular diseases
215. Serial changes in scleroderma and idiopathic interstitial lung disease
216. Lung function in patients with systemic sclerosis
217. Lungs in progressive systemic sclerosis
218. Alternate-day prednisone
219. Alternate-day corticosteroid therapy
220. Diffuse interstitial pneumonitis
221. The treatment of cryptogenic fibrosing alveolitis with immunosuppressant drugs
222. Aspekte der therapie von autoimmunerkrankungen' unter besonderer berucksichtigung ihrer pulmonalen manifestationen
223. Treatment of idiopathic pulmonary fibrosis
224. Interstitial lung disease resistant to corticosteroid therapy
225. Pilot study of penicillamine therapy in corticosteroid failure patients with widespread pulmonary fibrosis
226. Therapy of the idiopathic fibrosis of the lung. Experiences with three therapeutic principles: corticosteroids in combination with azathioprine, D-penicillamine and K-para-aminobenzoate
227. Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone
228. Interstitial pneumonia after prolonged treatment with cyclophosphamide
229. Cyclophosphamide therapy and interstitial pulmonary fibrosis
230. Diffuse alveolitis as complication of penicillamine treatment for rheumatoid arthritis
231. Acute leukemia following prolonged cytotoxic agent therapy
232. Chloroquine in the treatment of sarcoidosis
233. Treatment of sarcoidosis
234. Wegener's granulomatosis and related diseases
235. Small airways in idiopathic pulmonary fibrosis: comparison of morphologic and physiologic observations